文献速递系统性红斑狼疮

狼疮患者报告结局与SF-12对SLE损伤累积预测效度的比较

Comparison of predictive validity of the Lupus Patient-Reported Outcome and Short-Form-12 for damage accrual in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究在1326例系统性红斑狼疮(SLE)患者中比较疾病特异性Lupus PRO与通用量表SF-12对损伤累积的预测效度,采用复发事件生存模型分析。结果显示Lupus PRO健康相关生活质量(HR-QOL)及SF-12的PCS、RCS升高均与损伤累积降低相关,两者预测指标与判别性能相当。

要点

  • Lupus PRO的HR-QOL与SF-12的PCS、RCS均与SLE损伤累积降低相关
  • 两种量表的预测准确性与判别性能相当
  • 仅SF-12的PCS与糖皮质激素无关的SDI相关

核心结论

  • Lupus PRO与SF-12对SLE损伤累积的预测指标与判别性能相当,疾病特异性与通用生活质量量表均可作为核心结局集的候选。

研究设计与样本

  • 基于1326例SLE患者,比较基线Lupus PRO与SF-12评分对损伤累积的关联及预测准确性,采用复发事件生存模型分析。

主要发现

  • 基线Lupus PRO的HR-QOL较高者损伤累积显著更低(HR 0.94,95%CI 0.89-0.99)。
  • SF-12的PCS和RCS较高与损伤累积较低相关(HR 0.92,95%CI 0.86-0.98;HR 0.92,95%CI 0.86-0.99)。
  • Lupus PRO与SF-12的AIC、BIC、C-index和AUC相当。
  • 仅SF-12的PCS与糖皮质激素无关的SDI相关。

关键数值与推荐

  • 损伤累积定义为SDI增加1个单位。
  • Lupus PRO包含健康相关(HR)与非HR-QOL测量;SF-12指标为PCS、MCS和RCS。

临床怎么用

  • 临床可选择Lupus PRO或SF-12评估SLE患者生活质量并辅助预判损伤累积风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A core set of patient-reported outcomes (PROs) for systemic lupus erythematosus (SLE) has not been established, and no studies have compared predictive validity of disease-specific and generic quality of life (QOL) instruments. We aimed to compare the predictive validity of the Lupus PRO and Medical Outcomes Study Short-Form-12 (SF-12) for damage accrual in patients with SLE. METHODS: The Lupus PRO questionnaire contains both health-related (HR) and non-HR-QOL measures, whereas the SF-12 indices are the physical component summary (PCS), mental component summary (MCS), and role-social component summary (RCS). Damage accrual was evaluated using an increase of one unit in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We examined the association and predictive accuracy of the Lupus PRO and SF-12 scores at baseline for damage accrual using survival models for recurrent events. RESULTS: Among 1326 patients, those with a higher HR-QOL on Lupus PRO at baseline showed significantly lower damage accrual (hazard ratio: 0.94, 95% confidence interval [CI]: 0.89-0.99), whereas higher PCS and RCS of SF-12 were associated with lower damage accrual (0.92, 95% CI: 0.86-0.98; 0.92, 95% CI: 0.86-0.99). The Akaike Information Criterion, Bayesian Information Criterion, C-index, and area under the curve were comparable between the Lupus PRO and SF-12. Only higher PCS of the SF-12 was associated with glucocorticoid-independent SDI. CONCLUSION: Predictive metrics and discriminatory performance were comparable between the Lupus PRO and SF-12. Our findings highlight both disease-specific and generic QOL measurements can be valuable options for core set outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Onishi A, Tsuji H, Sasai T, et al. Comparison of predictive validity of the Lupus Patient-Reported Outcome and Short-Form-12 for damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 41649469. doi:10.1093/rheumatology/keag080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。